Home Data Calendar Blog

MORF

Tables

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Common Stock Value 0.000.000.000.000.000.000.000.000.000.000.00NANANANA
Weighted Average Number Of Diluted Shares Outstanding 39.5537.13NA36.5536.1833.53NA32.3730.36NANA30.00NANANA
Weighted Average Number Of Shares Outstanding Basic 38.2437.13NA36.5536.1833.53NA30.5330.3630.19NA30.00NANANA
Earnings Per Share Basic 0.70-0.85-0.58-0.69-0.77-0.63-0.570.18-0.52-0.55-0.63-0.30NANANA
Earnings Per Share Diluted 0.68-0.85-0.58-0.69-0.77-0.63-0.570.17-0.52-0.55-0.63-0.30NANANA

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Revenue From Contract With Customer Excluding Assessed Tax 60.242.389.563.123.853.275.9025.767.695.59-0.335.675.576.073.36
Revenue From Contract With Customer Including Assessed Tax 60.242.389.563.123.853.275.9025.767.695.59-0.335.675.576.073.36
Revenues 60.242.389.563.123.853.275.9025.767.695.59-0.335.675.576.073.36
Costs And Expenses 33.8934.0531.1028.2431.6924.5723.8820.7524.1123.3820.2515.5315.9812.209.33
Research And Development Expense 25.6526.4623.6620.9724.5518.6118.7516.0019.9218.9616.8212.6313.9110.377.29
General And Administrative Expense 8.237.597.447.287.145.955.134.754.204.423.432.902.081.832.04
Operating Income Loss 26.35-31.67-21.55-25.12-27.84-21.30-17.985.01-16.42-17.79-20.58-9.86-10.42-6.13-5.97
Interest Income Expense Nonoperating Net 0.480.190.130.080.040.030.110.230.410.891.091.391.121.060.66
Allocated Share Based Compensation Expense 7.626.765.645.795.314.443.023.002.492.541.380.990.670.500.60
Income Tax Expense Benefit 0.00NANANANANA-0.14-0.12-0.15-0.160.340.300.140.130.00
Profit Loss 26.84-31.48-21.40-25.04-27.82-21.28-17.755.35-15.86-16.75-19.83-8.86-9.43-5.20NA
Other Comprehensive Income Loss Net Of Tax -0.62-1.31-0.39-0.07-0.000.01-0.06-0.19-0.390.57-0.000.010.020.03NA
Net Income Loss 26.84-31.48-21.40-25.04-27.82-21.28-17.755.35-15.86-16.75-19.83-8.86-9.43-5.20-5.34
Comprehensive Income Net Of Tax 26.22-32.79-21.79-25.11-27.82-21.28-17.805.16-16.25-16.18-19.83-8.86-9.42-5.17-5.34

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Assets 413.88397.07426.29438.56439.48459.57242.38221.58212.00229.16247.44260.08178.61NA189.31
Liabilities 25.8983.7089.5988.4091.5790.6797.1991.2797.08101.02106.52100.73104.78NA102.05
Liabilities And Stockholders Equity 413.88397.07426.29438.56439.48459.57242.38221.58212.00229.16247.44260.08178.61NA189.31
Stockholders Equity 387.99313.37336.70350.17347.91368.89145.20130.30114.92128.13140.92159.35-65.98-57.23-52.55

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Assets Current 406.62389.49418.33435.40436.85456.85239.44218.40208.61225.55243.57257.04172.79NA187.12
Cash And Cash Equivalents At Carrying Value 141.18119.84171.43184.16399.40395.99102.0598.08133.12107.03101.56159.8144.2042.42185.90
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 141.74120.40171.99184.72399.68396.26102.3298.36133.40107.31101.83160.0844.4742.69186.18
Accounts Receivable Net Current 1.042.042.312.621.312.767.311.643.533.693.472.360.94NANA
Prepaid Expense And Other Assets Current 8.026.807.895.213.915.773.863.622.542.863.092.931.44NA1.22
Available For Sale Securities Debt Securities 256.38260.81236.70243.42NANA126.22NANANANANANANANA

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Property Plant And Equipment Net 2.372.372.582.582.332.392.612.823.023.223.452.722.53NA1.84
Other Assets Noncurrent 0.150.160.010.010.030.050.070.090.090.110.140.053.02NA0.06

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Liabilities Current 19.6843.7938.2641.7634.9134.0739.4435.5845.2836.8435.3526.4843.53NA34.90
Accounts Payable Current 3.883.504.803.185.252.273.853.023.884.625.173.292.91NA1.75
Accounts Payable And Accrued Liabilities Current 11.359.9912.848.427.697.2010.167.468.295.626.645.055.22NA3.24
Accrued Liabilities Current 1.480.940.961.010.971.250.680.960.820.721.011.171.68NA0.71
Contract With Customer Liability Current 4.4530.3120.6330.1521.8024.4225.27NANANANANANANANA

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Operating Lease Liability Noncurrent 3.113.483.84NANANANANANANANANANANANA

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Stockholders Equity 387.99313.37336.70350.17347.91368.89145.20130.30114.92128.13140.92159.35-65.98-57.23-52.55
Common Stock Value 0.000.000.000.000.000.000.000.000.000.000.00NANANANA
Additional Paid In Capital 633.10584.69575.23566.91539.54532.70287.73255.03244.81241.78238.38236.982.80NA1.63
Retained Earnings Accumulated Deficit -242.70-269.54-238.05-216.65-191.61-163.80-142.51-124.76-130.12-114.26-97.51-77.68-68.82NA-54.19
Accumulated Other Comprehensive Income Loss Net Of Tax -2.42-1.79-0.48-0.09-0.02-0.02-0.020.030.220.610.04NANANANA

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Net Cash Provided By Used In Operating Activities -22.82-28.15-20.59-24.58-17.91-20.39-14.423.73-16.36-18.94-14.07-13.70-14.070.1992.56
Net Cash Provided By Used In Investing Activities 3.28-26.075.19-211.9619.8573.75-11.29-46.0541.9123.62-44.2034.2017.68-143.67-0.16
Net Cash Provided By Used In Financing Activities 40.882.632.6721.581.48240.5829.687.280.540.800.0395.10NANA-0.41

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Net Cash Provided By Used In Operating Activities -22.82-28.15-20.59-24.58-17.91-20.39-14.423.73-16.36-18.94-14.07-13.70-14.070.1992.56
Net Income Loss 26.84-31.48-21.40-25.04-27.82-21.28-17.755.35-15.86-16.75-19.83-8.86-9.43-5.20-5.34
Profit Loss 26.84-31.48-21.40-25.04-27.82-21.28-17.755.35-15.86-16.75-19.83-8.86-9.43-5.20NA
Increase Decrease In Accounts Receivable -1.00-0.27-0.311.30-1.45-4.555.68-1.90-0.150.221.101.420.570.38NA
Increase Decrease In Accounts Payable 0.28-1.301.81-2.222.94-1.570.82-0.84-0.74-0.311.620.380.021.14-0.00
Share Based Compensation 7.626.765.645.795.314.443.023.002.492.541.380.990.670.500.60

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Net Cash Provided By Used In Investing Activities 3.28-26.075.19-211.9619.8573.75-11.29-46.0541.9123.62-44.2034.2017.68-143.67-0.16
Payments To Acquire Property Plant And Equipment 0.000.050.460.360.150.050.070.090.090.290.710.390.500.560.17

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Net Cash Provided By Used In Financing Activities 40.882.632.6721.581.48240.5829.687.280.540.800.0395.10NANA-0.41

    2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31
Revenues 60.242.389.563.123.853.275.9025.767.695.59-0.335.675.576.073.36
Abb Vie 0.0020.00NA20.00NANANANANANANANANANANA
Abb Vie, License 58.440.816.201.482.071.50-12.3323.655.29NANANANANANA
Janssen Pharmaceuticals Inc, Reimbursement Revenue 1.031.011.031.281.311.321.441.631.84NANANANANANA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue 0.760.562.370.370.470.440.740.480.56NANANANANANA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue First Two Programs 0.0010.00NANANANANANANANANANANANANA
Janssen Pharmaceuticals Inc, License 1.791.573.401.651.781.772.172.112.40NANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 60.242.389.563.123.853.275.9025.767.695.59-0.335.675.576.073.36
Abb Vie 0.0020.00NA20.00NANANANANANANANANANANA
Abb Vie, License 58.440.816.201.482.071.50-12.3323.655.29NANANANANANA
Janssen Pharmaceuticals Inc, Reimbursement Revenue 1.031.011.031.281.311.321.441.631.84NANANANANANA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue 0.760.562.370.370.470.440.740.480.56NANANANANANA
Janssen Pharmaceuticals Inc, Upfront Payment Revenue First Two Programs 0.0010.00NANANANANANANANANANANANANA
Janssen Pharmaceuticals Inc, License 1.791.573.401.651.781.772.172.112.40NANANANANANA
Revenue From Contract With Customer Including Assessed Tax 60.242.389.563.123.853.275.9025.767.695.59-0.335.675.576.073.36

Plots across concepts


IncomeStatement
Other Comprehensive Income Loss Net Of Tax
Expenses
Income Tax Expense Benefit
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Property Plant And Equipment Net
Current Assets
Accounts Receivable Net Current
NonCurrent Assets
Other Assets Noncurrent
Liabilities
Accounts Payable And Accrued Liabilities Current And Noncurrent
Current Liabilities
Operating Lease Liability Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
Shares
Weighted Average Number Of Shares Outstanding Basic
OperatingLeaseLiability
Operating Lease Liability Current
NonoperatingIncomeExpense
Other Nonoperating Income Expense

Line plots across dimensions of each concept


Cost Ratio
us-gaap:CounterpartyName, us-gaap:ProductOrService
(None, 'us-gaap:License')
Cost  Ratio us-gaap: Counterparty Name, us-gaap: Product Or Service
TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService
('morf:JanssenPharmaceuticalsInc', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Counterparty Name, us-gaap: Product Or Service
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService
('morf:JanssenPharmaceuticalsInc', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service
us-gaap:CostsAndExpenses
us-gaap:CounterpartyName, us-gaap:ProductOrService
(None, 'us-gaap:License')
Costs And Expensesus-gaap: Counterparty Name, us-gaap: Product Or Service
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType
(None,)
Allocated Share Based Compensation Expenseus-gaap: Award Type
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueInputsLevel2', 'us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Fair Value Hierarchy Level, us-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService
('morf:JanssenPharmaceuticalsInc', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService
('morf:JanssenPharmaceuticalsInc', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Counterparty Name, us-gaap: Product Or Service